4D Molecular Therapeutics Inc [FDMT] stock prices are up 6.66% to $29.00 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The FDMT shares have gain 6.38% over the last week, with a monthly amount glided 51.99%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 12, February 2024, 4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024. In a post published today on Yahoo Finance, 4D-310 demonstrated clinically meaningful cardiac endpoint improvements through 12-24 months in contractility (echocardiography), peak VO2 (cardiopulmonary exercise testing) and/or cardiac quality of life (KCCQ) in all five evaluable patients.
From an analyst’s perspective:
Previously, RBC Capital Mkts started tracking the stock with Outperform rating on October 26, 2023, and set its price target to $25. On October 24, 2023, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $32 on the stock. Leerink Partners upgraded its rating to a Outperform but stick to its price target of $24 on October 18, 2023. Chardan Capital Markets initiated its recommendation with a Buy and recommended $30 as its price target on July 05, 2023. BMO Capital Markets started tracking with a Outperform rating for this stock on January 30, 2023, and assigned it a price target of $50. In a note dated November 18, 2022, H.C. Wainwright initiated an Buy rating and provided a target price of $36 on this stock.
The stock price of 4D Molecular Therapeutics Inc [FDMT] has been fluctuating between $9.44 and $35.61 over the past year. Currently, Wall Street analysts expect the stock to reach $44 within the next 12 months. 4D Molecular Therapeutics Inc [NASDAQ: FDMT] shares were valued at $29.00 at the most recent close of the market. An investor can expect a potential return of 51.72% based on the average FDMT price forecast.
Analyzing the FDMT fundamentals
The 4D Molecular Therapeutics Inc [NASDAQ:FDMT] reported sales of 21.99M for trailing twelve months, representing a surge of 3940.80%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 27.71 points at the first support level, and at 26.42 for the second support level. However, for the 1st resistance point, the stock is sitting at 29.71, and for the 2nd resistance point, it is at 30.42.
4D Molecular Therapeutics Inc [FDMT] reported earnings per share of -$0.24 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.59/share, meaning a difference of $0.35 and a surprise factor of 59.30%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.77 per share as compared to estimates of -$0.81 per share, a difference of $0.04 representing a surprise of 4.90%.
Ratios To Look Out For
It’s worth pointing out that 4D Molecular Therapeutics Inc [NASDAQ:FDMT]’s Current Ratio is 18.07. Also, the Quick Ratio is 18.07, while the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 65.07, the price to book ratio is 3.76.
Transactions by insiders
Recent insider trading involved Bizily Scott, Chief Legal Officer, that happened on Feb 16 when 1750.0 shares were sold. Chief Executive Officer, Kirn David completed a deal on Feb 08 to sell 92001.0 shares. Meanwhile, Chief Legal Officer Bizily Scott sold 6244.0 shares on Feb 08.
